Nuclear matrix proteins, polynucleotide sequences encoding them, and their uses
AssigneeUniversity of Pittsburgh
InventorRobert H. Getzenberg
Life of this patent
Estimating the term…
Abstract
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue, particularly prostate tissue, are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Claims41
A method of determining the presence or absence of a metastatic cell, comprising determining the presence or absence of a nuclear matrix protein that is present in a metastatic cell but absent in a non-metastatic cell.
A purified nuclear matrix protein which is present in cancerous prostate cells but absent in normal prostate cells selected from the group consisting of:
- (a) D-1 having a molecular weight of about 63 kD and a pI of about 8.55,
- (b) D-2 having a molecular weight of about 40 kD and a pI of about 5.91, and
- (c) D-3 having a molecular weight of about 33 kD and a pI of about 6.97;
- or an immunogenic fragment of one of said proteins (a)-(c).
A purified nuclear matrix protein that is present in normal prostate cells but absent in cancerous prostate cells, and that is selected from the group consisting of:
- (a) NDP-1 having a molecular weight of about 95 kD and a pI of about 6.74,
- (b) NDP-2 having a molecular weight of about 57 kD and a pI of about 8.33,
- (c) NDP-3 having a molecular weight of about 57 kD and a pI of about 8.0,
- (d) NDP-4 having a molecular weight of about 47 kD and a pI of about 5.26,
- (e) NDP-5 having a molecular weight of about 47 kD and a pI of about 5.80,
- (f) NDP-6 having a molecular weight of about 41 kD and a pI of about 6.83,
- (g) NDP-7 having a molecular weight of about 37.2 kD and a pI of about 7.05,
- (h) NDP-8 having a molecular weight of about 36.9 kD and a pI of about 7.35,
- (i) NDP-9 having a molecular weight of about 35 kD and a pI of about 6.25, and
- (j) NDP-10 having a molecular weight of about 32.5 kD and a pI of about 5.46;
- or an immunogenic fragment of one of said proteins (a)-(j).
A purified nuclear matrix protein which is present in metastatic prostate cells but absent in non-metastatic prostate cells selected from the group consisting of:
- (a) AM-1 having a molecular weight of about 40 kD and a pI of about 6.73, and
- (b) AM-2 having a molecular weight of about 36 kD and a pI of about 8.33;
- or an immunogenic fragment of one of said proteins (a) or (b).
A purified nuclear matrix protein which is absent in metastatic prostate cells but present in non-metastatic prostate cells selected from the group consisting of:
- (a) G-1 having a molecular weight of about 55 kD and a pI of about 6.48, and
- (b) G-2 having a molecular weight of about 52 kD and a pI of about 6.93;
- or an immunogenic fragment of one of said proteins (a) or (b).
An antibody directed against a purified nuclear matrix protein or an immunogenic fragment thereof, said protein being selected from the group consisting of:
- (i) a protein which is present in cancerous prostate cells but absent in normal prostate cells selected from the group consisting of:
- (a) D-1 having a molecular weight of about 63 kD and a pI of about 8.55,
- (b) D-2 having a molecular weight of about 40 kD and a pI of about 5.91, and
- (c) D-3 having a molecular weight of about 33 kD and a pI of about 6.97;
- (ii) a protein which is present in normal prostate cells but absent in cancerous prostate cells selected from the group consisting of:
- (a) NDP-1 having a molecular weight of about 95 kD and a pI of about 6.74,
- (b) NDP-2 having a molecular weight of about 57 kD and a pI of about 8.33,
- (c) NDP-3 having a molecular weight of about 57 kD and a pI of about 8.0,
- (d) NDP-4 having a molecular weight of about 47 kD and a pI of about 5.26,
- (e) NDP-5 having a molecular weight of about 47 kD and a pI of about 5.80,
- (f) NDP-6 having a molecular weight of about 41 kD and a pI of about 6.83,
- (g) NDP-7 having a molecular weight of about 37.2 kD and a pI of about 7.05,
- (h) NDP-8 having a molecular weight of about 36.9 kD and a pI of about 7.35,
- (i) NDP-9 having a molecular weight of about 35 kD and a pI of about 6.25, and
- (j) NDP-10 having a molecular weight of about 32.5 kD and a pI of about 5.46;
- (iii) a protein which is present in metastatic prostate cells but absent in non-metastatic prostate cells selected from the group consisting of:
- (a) AM-1 having a molecular weight of about 40 kD and a pI of about 6.73, and
- (b) AM-2 having a molecular weight of about 36 kD and a pI of about 8.33;
- and
- (iv) a protein which is absent in metastatic prostate cells but present in non-metastatic prostate cells selected from the group consisting of:
- (a) G-1 having a molecular weight of about 55 kD and a pI of about 6.48, and
- (b) G-2 having a molecular weight of about 52 kD and a pI of about 6.93.
Dependencies are inferred from the claim text.